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Abstract
Objective: Platelet surface receptors are also present subcellularly in organelle mem-
branes and can be expressed on the surface upon platelet activation. However, some 
receptors were reported to be decreased after activation. We analyzed the mecha-
nism of activation-dependent expression for different receptors.
Methods: Flow cytometry using platelet-rich plasma or washed platelets was used 
to analyze receptor-expression changes after platelet activation by glycoprotein (GP) 
VI–specific agonists, crosslinked collagen-related peptide (CRP-XL) and convulxin 
(Cvx), and thrombin. Platelets prelabeled with fluorescent antibody specific for a 
receptor were allowed to adhere on immobilized collagen or fibrinogen and post-
stained with antibody against the same receptor labeled with another fluorophore, 
allowing us to differentiate preexisting receptors from newly expressed receptors.
Results: Surface expression of αIIbβ3 increased in CRP-XL–, Cvx-, or thrombin-stim-
ulated platelets, but GPIb decreased due to shedding and internalization. Both total 
and dimeric GPVI increased in thrombin-induced platelets, but decreased in platelets 
stimulated by Cvx, as a result of internalization. The larger platelets showed a greater 
increase in surface receptor (α2β1, αIIbβ3, GPVI, GPIb) expression upon activation 
compared to the smaller ones. Pre- and postlabeling with antibody specific for the 
same receptor, but conjugated with different fluorophores, allowed us to differenti-
ate the receptors expressed on the surface of resting platelets from receptors newly 
exposed to the surface upon platelet activation.
Conclusions: Increased receptor expressions after activation are mainly manifested 
in the larger platelets. On platelets adhered on fibrinogen, the newly expressed re-
ceptors, especially GPVI, are localized in the lamellipodia of the spread platelets.
K E Y W O R D S
blood platelets, glycoprotein Ib, platelet activation, platelet glycoprotein GPIIb-IIIa complex, 
platelet membrane glycoprotein VI, platelet membrane glycoproteins,  receptors
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Essentials
• Activation-dependent platelet surface expression of different receptors was analyzed.
• Changes in surface expression depended on both the receptor and the platelet agonist.
• Newly expressed receptors localize on lamellipodia of platelets spread on fibrinogen.
• Increased receptor expressions upon activation are mainly manifested in larger platelets.
1  | INTRODUCTION
Platelets are anucleate small blood cells, but they have several in-
tracellular organelles and membrane systems whose localization 
and morphology are changed upon platelet activation by vari-
ous stimulants. Activation transforms the smooth disclike shape 
of resting platelets to a disturbed spherical shape with numerous 
filopodial extrusions and lamellipodia, accompanied by marked 
changes in subcellular organelle localization. Secretory dense 
granules and α-granules extrude their contents to the extracellular 
medium or through the inside space of the open canalicular sys-
tem (OCS), and granule membranes fuse with the plasma or OCS 
membrane.1‒4 Major receptor proteins contained in the OCS and 
α-granule membranes, including glycoprotein (GP) Ib and αIIbβ3,1,2 
become exposed to the surface when their membranes fuse with 
the platelet plasma membrane. This may explain increased surface 
αIIbβ3 expression in activated platelets,1,2 but a decrease in sur-
face GPIb5,6 upon activation suggests that other mechanisms may 
be involved.
Platelets are essential for primary hemostasis since they ad-
here to subendothelial collagen exposed by vessel injury, become 
activated, aggregate, and form a thrombus to arrest bleeding. 
Hyperactive platelets, however, lead to formation of unwanted 
thrombi, which can detach and travel to distal areas, causing isch-
emic stroke or cardiovascular disease (CVD). Larger platelet size, 
measured as increased mean platelet volume (MPV), is a risk fac-
tor for cardiovascular disease CVD.7,8 MPV increases with age in 
mice, which might explain the increasing CVD risk in the elderly.9 
Circumstantial evidence suggests that large platelets are more ac-
tive, but there is yet no direct evidence for this and why this may 
be so.
The aim of the present study is to compare larger platelets with 
the whole platelet population in terms of their surface expressions 
of receptors involved in thrombus formation in response to plate-
let activation using a clinically available method, flow cytometry. 
In resting platelets, surface expressions of GPIb, αIIbβ3, α2β1, and 
GPVI were higher in the larger platelets, commensurate with their 
larger surface area. Expressions of αIIbβ3 and α2β1 were increased 
in activated platelets, but GPIb and GPVI decreased due to shed-
ding, internalization, or both. Increased exposure of intracellular re-
ceptors upon activation was most prominent in the larger platelets. 
These results suggest that platelets are a heterogeneous population, 
not only with respect to size but importantly with respect to activity 
and that the large platelets are the main determinants of platelet 
activation and function.
2  | MATERIALS AND METHODS
2.1 | Materials
GPVI dimer–specific, noninhibitory 204-11 Fab10 was previously 
reported. Other mouse monoclonal antibodies: 1G511 (anti-pan 
GPVI; Biocytex, Marseille, France), anti-GPIb antibodies AK2 
(Novus Biologicals, Littleton, CO, USA) and clone 486805 (R&D 
Systems, Minneapolis, MN, USA); anti-αIIbβ3 (M148; Abcam, 
Cambridge, UK); anti-α2 (Gi9; Abcam), anti-CD62P (AK6; Abcam); 
fluorescein isothiocyanate–conjugated antiactivated integrin 
αIIbβ3 procaspase-activating compound-1 (PAC-1; BD Biosciences, 
San Jose, CA, USA). For some experiments, antibodies were la-
beled with Alexa Fluor-488 or -647 by an Invitrogen labeling kit 
(Thermo Fisher Scientific, Waltham, MA, USA). Convulxin (Cvx)12 
and crosslinked collagen-related peptide (CRP-XL)13 were previ-
ously reported.
2.2 | Flow cytometry to measure surface 
receptor expression
Platelet-rich plasma (PRP), prepared from acid-citrate-dex-
trose–anticoagulated blood from healthy volunteers,10 was 
diluted 4-fold with modified HEPES (4-[2-hydroxyethyl]-1pipera-
zineethanesulfonic acid)–Tyrode’s buffer (HT: 136 mmol/L NaCl, 
2.7 mmol/L KCl, 0.42 mmol/L NaH2PO4, 5.5 mmol/L glucose, 
5 mmol/L HEPES, pH 7.4) or washed platelets (5 × 107 cells/
mL, HT) were prepared as before.10 Platelets were activated by 
CRP-XL (5 μg/mL), Cvx (0.5 μg/mL), or thrombin (0.2 U/mL) for 
4 minutes at 37°C. Samples were prepared for flow cytometry 
(Accuri C6, BD Biosciences, San Jose, CA, USA),10 with receptor-
specific primary antibody and Alexa Fluor-488–conjugated anti-
mouse Fab (50 μg/mL; Jackson Immuno-Research Laboratories, 
West Grove, PA, USA) as secondary antibody. The negative 
control was isotype control IgG or control mouse Fab. Platelet 
receptor expression was expressed as median fluorescence in-
tensity (MFI) obtained for binding of receptor-specific antibody.
In each experiment, the whole platelet population (P1) of a do-
nor’s platelets was divided into 2 subpopulations according to size 
by gating in the forward scatter/side scatter (FSC/SSC) plot: The 
larger half was defined as P2 (larger platelets) and the smaller half 
was defined as P3 (smaller platelets; Figure 1A shows an example). 
Numbers of platelets in each subpopulation are calculated as per-
centage of total events.
     |  287MOROI et al.
2.3 | Analysis of receptor expression in 
fixed platelets
Washed platelets (200 μL, 5 × 108 cells/mL,) were activated 
(CRP-XL or thrombin) for 4 minutes and mixed with 200 μL cold 
8% formaldehyde/0.4% glutaraldehyde/PBS; after 30 minutes on 
ice, the mixture was diluted with 4 mL cold citrate-buffered sa-
line (CBS: 6.85 mmol/L citrate, 130 mmol/L NaCl, 4 mmol/L KCl, 
5.5 mmol/L glucose buffer, pH 6.5) containing 5 mmol/L ethylen-
ediaminetetraacetic acid (EDTA) and centrifuged in a microfuge 
(1000 g, 10 minutes). Each pellet was resuspended in 100 μL 
HT, and antibody binding was determined by flow cytometry. 
Formaldehyde/glutaraldehyde solution was used, as it has less ef-
fect on cell membrane phospholipid distribution14 and better main-
tained platelet antibody binding.
2.4 | Immunoblotting
Washed platelets (200 μL, 109 cells/mL) were activated with CRP-XL 
(5 μg/mL), Cvx (0.5 μg/mL), or thrombin (0.5 U/mL) for 5 minutes 
at 37°C followed by 30 minutes at room temperature. Suspensions 
were centrifuged to separate supernatants and platelet pellets, which 
were dissolved with 200 μL 6 mol/L urea/1% SDS. Non-reducing 
F I G U R E  1   Flow cytometric analysis of large platelets. A, Resting and crosslinked collagen-related peptide (CRP-XL; 5 μg/mL)-activated 
platelets in platelet-rich plasma (PRP) were analyzed by flow cytometry. Both the resting and CRP-XL–activated platelets were gated into 
2 populations from their FSC/SSC plots (left plots): P1 (the total platelet population) and the larger half of P1 (P2). Since the Acuri C6 flow 
cytometer cannot delineate the larger half of the population from the lower half, we manually drew the gating line for each preparation 
analyzed. The fluorescence of P1 and that of P2, expressed as median fluorescence intensity (MFI), are shown in the middle and right plots 
for the resting and CRP-activated platelets. B, Each P2/P1 ratio (reported as %) is calculated from the MFI of P1 and the MFI of P2. This 
figure summarizes from results for PRP and washed platelets, with different activators and specific antibodies (shown in parentheses) to 
determine expressions of total GPVI (1G5), GPVI-dimer (204-11 Fab), integrin α2β1 (Gi9), integrin αIIbβ3 (M148), and GPIb (AK2). Each bar 
in the graphs and their associated error bar show the mean ± standard deviation of the indicated number of determinations. P1/P2 for 
each receptor of platelets activated with CRP-XL, convulxin (Cvx), or thrombin was compared to the respective P1/P2 of resting platelets. 
For PRP, CRP-XL increased the ratio of GPVI-dimer (P = .000, n = 5) and ratios of α2β1 (P = .08, n = 4) and αIIbβ3 (P = .08, n = 5) tended to 
be higher. Cvx also increased the ratio of GPVI-dimer (P = .007, n = 6), α2β1 (P = .03, n = 4), GPIb (P = .02, n = 4), and αIIbβ3 (P = .02, n = 5). 
However, thrombin only increased the ratio of GPVI-dimer (P = .03, n = 4). For washed platelets, the P2/P1 ratios are increased compared to 
those of the corresponding resting platelets after the activation by CRP-XL (GPVI dimer: P = .01, n = 8; α2β1: P = .003, n = 5; GPIb: P = .11, 
n = 7; αIIbβ3: P = .002, n = 7); Cvx (GPVI dimer: P = .05, n = 7; α2β1: P = .002, n = 5; GPIb: P = .00, n = 7; αIIbβ3: P = .00, n = 6); and thrombin 
(GPVI-dimer: P=<0.00, n = 13; α2β1: P = .02, n = 5; GPIb: P = .005, n = 7; αIIbβ3: P < .0001, n = 11). *P ≤ .05, **P ≤ .005, ***P ≤ .0005, 
****P < .0001
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Laemmli's SDS sample buffer was added to each sample and heated 
at 100°C for 1 minute. Each sample (5 μL for the pellet, 15 μL for the 
supernatant) was electrophoresed on a 3% to 12% acrylamide SDS 
gel, immunoblotted with 1G5 or clone 486805 and analyzed by the 
Odyssey CLx (LI-COR Biosciences, Lincoln, NE, USA).
2.5 | Confocal imaging of internalization and surface 
receptor expression
2.5.1 | GPIb and GPVI internalization
Washed platelets were incubated with Alexa Fluor-488–labeled 204-
11 Fab or clone 486805 mAb (4 μg/mL, 30 minutes) and washed once 
with CBS. The prelabeled platelets were activated with Cvx (0.5 μg/
mL) or thrombin (0.5 U/mL) for 5 minutes at 37°C; added with an equal 
volume of ice-cold 8% formaldehyde/0.4% glutaraldehyde/phosphate 
buffered saline (PBS), followed by 30-minute on ice; washed once with 
5 mmol/L EDTA in CBS; and resuspended in HT. Platelet suspensions 
were aliquoted on poly-l-lysine–coated MatTek dishes and centrifuged 
(1000 g, 5 minutes) in a Mistral 2000 (DJB Labcare Ltd., Newport 
Pagnell, UK). Dishes were washed with PBS, blocked with 0.5% bo-
vine serum albumin (BSA)/PBS, reacted with Alexa Fluor-647–labeled 
M148 (anti-CD41 mAb) for 60 minutes, and processed for imaging with 
an FV300 IX81 laser-scanning confocal microscope with a 60 oil im-
mersion objective (Olympus UK, Southend-on-Sea, UK).15
2.5.2 | Receptors newly exposed upon 
platelet activation
Washed platelets prelabeled with Alexa Fluor-488–labeled clone 
486805 mAb, 204-11 Fab or M148 were allowed to adhere to Horm-
collagen– or fibrinogen-coated MatTek dishes (60 minutes, 37°C). 
Dishes were washed with PBS, and adhered platelets were fixed 
with 10% formaldehyde and blocked with 1% BSA/PBS. The plate-
lets prelabeled with 204-11 Fab, clone 48605 Mab, and M148 were 
reacted with Alexa Fluor-647–labeled 1G5, 486805 Mab, and M148, 
respectively; washed; and imaged.
2.5.3 | Verification of GPVI internalization
1G5 was labeled with sulfo-NHS-SS-biotin (Thermo Fisher Scientific, 
Waltham, MA, USA) to form the biotinylated antibody (1G5-SS-biotin). 
Washed platelets were incubated with 1G5-SS-biotin and Alexa Fluor 
647–streptavidin. Then excess biotin was added; 10 minutes later, the 
mixture was diluted with CBS and centrifuged to obtain the platelet 
pellet. The pellet was resuspended in HT, and aliquots were activated 
with Cvx (1 μg/mL) or thrombin (0.2 units/mL), followed by addition of 
TCEP (tris[2-carboxyethyl]phosphine; 28 mmol/L, final; Thermo Fisher 
Scientific, Waltham, MA, USA). Samples were processed for confocal 
microscopy to visualize the remaining GPVI-associated fluorescence.
2.6 | Statistical analysis
Paired Student’s t-test (Prism v8.9, GraphPad Software, La Jolla, CA, 
USA) was applied to compare differences between activated plate-
lets and their corresponding resting platelets.
3  | RESULTS
3.1 | Large platelets have higher levels of surface 
receptor expression
From the SSC/FSC scatter plot, resting platelets of each donor 
were gated into the larger platelets (P2) of the total population (P1; 
Figure 1A, resting platelets). Because each donor’s platelets showed 
a different size distribution, gating was tailored to each donor’s FSC/
SSC plot. P2 of resting platelets showed 1.5-fold higher binding of 
anti-GPVI dimer (204-11 Fab) than P1. CRP-XL activation slightly 
changed the scatter plot (Figure 1A, activated) and P2, defined by 
the same gating as used for resting platelets, exhibited 1.9-fold 
higher 204-11 binding than P1.
Thus, we determined if the P2 population also showed higher 
numbers of other platelet surface receptors, using specific primary 
antibodies: total GPVI (1G5), GPIb (AK2), αIIbβ3 (M148), and α2β1 
(Gi9), using isotype IgG (control) to determine background fluores-
cence (black bar [control] in Figure 1B) under each condition (resting, 
CRP, Cvx, thrombin).
P2/P1 of control resting platelets was about 130%, show-
ing that P2 bound more control IgG than P1, indicating that P2 
platelets have a larger cell surface area. For all receptors, except 
for total GPVI, P2/P1 ratios were similar to that of the control. 
The higher P2/P1 for total GPVI (Figure 1B: PRP, P < .0001, n = 7; 
washed platelets, P < .0004, n = 5) is due to the ability of 1G5 to 
activate platelets.11
For PRP added with agonist, only some of the P2/P1 data 
were significantly higher than the respective resting control: for 
CRP: dGPVI (P < .0001, n = 5); for Cvx: dGPVI (P < .007, n = 5), 
α2β1 (P < .028, n = 4), GPIb (P < .020, n = 4), αIIbβ3 (P < .019, 
n = 5); for thrombin: dGPVI (P < .025, n = 4). Although the P2/P1 
for each receptor was higher than the ratio in the resting plate-
lets for each donor, there was a high variability among values 
for different donors. The high fibrinogen level in PRP may have 
had some effect on antibody binding in the activated platelets, 
so we measured P2/P1 in washed platelets for most of our other 
experiments.
In contrast to PRP, activated washed platelets show higher P2/
P1 for the examined receptors, except for dGPVI and GPIb in Cvx- 
and CRP-induced platelets, respectively. Platelets are a heteroge-
neous population with respect to surface receptor expression in 
both the resting state and the activated state. The washed-plate-
let results suggest that among the activated platelets, the larger 
platelet population showed the highest increase in surface recep-
tor expression.
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3.2 | Receptor expression after platelet activation
Surface receptor expressions in platelets activated by CRP-XL, 
Cvx, and thrombin were determined and compared to expres-
sion of each receptor in resting platelets (Figure 2). For the total 
platelet population (P1) of PRP (Figure 2A), both total GPVI and 
GPVI dimer very markedly decreased after stimulation by Cvx (GPVI 
dimer: P = .03, n = 5; total GPVI: P = .000, n = 4), but no significant 
changes in expression of either in response to CRP-XL or thrombin. 
α2β1 and αIIbβ3 expressions tended to increase after activation but 
F I G U R E  2   Changes of receptor expression after platelet activation. Receptor expressions are measured by flow cytometry using 
different agonists and receptor-specific antibodies. Receptor expressions in platelets activated by CRP, convulxin (Cvx), or thrombin (Thr) are 
compared to the respective value in resting platelets (rest). A, P1 (total platelet population) of platelet-rich plasma (PRP); B, P2 subpopulation 
of PRP (A); C, P1 of washed platelets; D, P2 subpopulation of washed platelets (C). Each bar in the graphs and their associated error bar show 
the mean ± SD of the indicated number of determinations. *P ≤ .05, **P ≤ .005, ***P ≤ .0005, ****P < .0001. Detailed descriptions of the 
statistical analyses are given in the Results section
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not significantly, and only Cvx induced significant increases (α2β1: 
P = .02, n = 4 and αIIbβ3: P = .004, n = 5). Each agonist decreased 
surface GPIb expression: CRP-XL (P = .02, n = 5), Cvx (P < .005, n = 5), 
and thrombin (P = .08, n = 5).
P1 of washed platelets (Figure 2C) showed changes similar to those 
for P1 of PRP, but they became more significant because of the larger 
number of measurements. GPVI expression is strongly decreased by 
Cvx (GPVI dimer: P < .0001, n = 7; total GPVI: P < .0001, n = 6). GPVI 
dimer, but not total GPVI, is slightly increased by thrombin (P = .0158, 
n = 13). None of the agonists changed α2β1 expression. αIIbβ3 expres-
sion tended to increase after activation (CRP-XL: P = .03, n = 7; Cvx: 
P = .08, n = 6; thrombin: P = .003, n = 11). Surface GPIb expression, 
however, strongly decreased in response to each agonist: CRP-XL 
(P = .02, n = 7), Cvx (P < .0001, n = 7), and thrombin (P < .0001, n = 7).
If we compare the differences in receptor expression in the P2 
population of PRP and washed platelets (Figure 2B,D), which has 
higher expression of each receptor than the total population (P1), 
the changes in surface receptor expression upon activation are even 
more dramatic.
To confirm these results, we determined receptor expres-
sion in stimulated washed platelets that were subsequently 
fixed with formaldehyde/glutaraldehyde; 204-11 Fab was not 
used in these experiments, as it does not react with fixed plate-
lets. These activated and fixed platelets showed similar recep-
tor changes; Cvx, especially, strongly reduced GPVI expression 
(Figure 3A).
3.3 | Time course and agonist-concentration 
dependency of receptor expression in 
activated platelets
Flow cytometry of activated platelets (Figure 3B) showed that total 
GPVI expression is decreased by Cvx but increased by thrombin in a 
similar time scale: changes were evident by 0.5 minutes in some ex-
periments, well detectable by 1 minute, and maximal before 5 min-
utes. Thus, the receptor-expression changes are rapid, on the time 
scale of platelet aggregation.
Thrombin-induced changes in expressions of GPVI dimer, 
P-selectin, and activated αIIbβ3 in P1-P3 were measured using 
204-11 Fab, anti-CD62P, and PAC-1 antibodies, respectively. 
All 3 receptors increased dose dependently with thrombin, 
but increases in P2 were much greater than those in P1 and P3 
(Figure 4A). Increase of GPVI dimer expression in P3 platelets 
was much less, and expressions of CD62P and active αIIbβ3 in P2 
were more than 2-fold those in P3. Since anti-CD62P and PAC-1 
bind only to activated platelets, these results indicate that the 
F I G U R E  3   Analyses of receptor expressions using fixed 
platelets. A, Receptor expressions in fixed platelets. After platelets 
were activated, as described in Figure 2, they were fixed, stained 
using specific antibodies for the indicated receptors, and receptor 
expressions determined by flow cytometry. The increase or 
decrease of specific receptors in fixed platelets were similar to 
those obtained with native platelets. GPVI expression is decreased 
by convulxin (Cvx; P = .003, n = 8), but increased by crosslinked 
collagen-related peptide (CRP-XL) and thrombin (P = .003 and 
P = .003, respectively, n = 8). Integrin α2β1 tended to increase, 
although not reaching statistical significance, in platelets activated 
by CRP-XL (P = .03, n = 4), Cvx (P = .13, n = 3), or thrombin (P = .06, 
n = 3). αIIbβ3 increased after the activation by CRP-XL (P = .002, 
n = 4) or Cvx (P = .03, n = 3) and tended to increase in platelets 
activated by thrombin (P = .12, n = 3). The expression of GPIb 
decreased significantly in platelets activated by Cvx (P = .02, n = 3) 
and tended decrease in platelets activated by CRP-XL (P = .19, 
n = 4) or thrombin (P = .07, n = 3). The coulumms show the means 
of the measurements and the error bars shows their SD. *P ≤ .05, 
**P ≤ .005, ***P ≤ .0005, ****P < .0001. B, Time course of the 
change in GPVI expression after activation. Washed platelets 
were activated by thrombin (0.5 units/mL) or Cvx (1 μg/mL) and 
incubated at 37°C. After the indicated time, aliquots of platelets 
were removed, fixed, and then analyzed by flow cytometry for total 
GPVI using 1G5 antibody, as described in the Methods section. 
Expression of total GPVI is increased by thrombin and decreased by 
Cvx in a rapid time course
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major contributor to the measured increase in activation marker 
expression in the total population of activated platelets is the P2 
population. Increases of receptor expression observed at 0.005-
0.01 units/mL thrombin were consistent with the thrombin sensi-
tivity of a typical platelet aggregation assay.
Figure 4B shows the number of platelets distributed to P2 
and P3 in terms of percentage of total events. If smaller plate-
lets become larger upon activation (eg, platelet dimerization), the 
number in P2 should increase, while those in P3 should decrease. 
However, the percentage of total events increased slightly in 
P3 and decreased slightly in P2, suggesting that the platelets 
originally distributed in P2 would have increased their surface 
receptor expression. The slight decrease in the percentage of 
total events in P2 would be due to formation of aggregates.
3.4 | Analysis of GPIb and GPVI shedding
Platelet activation by CRP-XL, Cvx, or thrombin decreased surface GPIb 
expression, and activation by Cvx strongly decreased surface GPVI 
(Figures 2A-D and 3A). Two mechanisms may cause these decreases—
shedding or internalization. Shedding was assessed by activating washed 
platelets with CRP-XL, Cvx, or thrombin under the same conditions as 
those used for flow cytometry; platelet pellet and supernatant were 
F I G U R E  4   Concentration-dependent 
receptor expression of activation-
dependent antigens P-selectin and 
activated αIIbβ3. All data shown in 
this figure are representative of 3 
experiments, giving similar results, 
using platelets from different donors. 
A, Washed platelets were activated by 
increasing thrombin concentrations and 
expressions of GPVI dimer, P-selectin, 
and activated αIIbβ3 were measured 
using antibodies 204-11 Fab, AK6, and 
PAC-1, respectively. Expressions of 
receptors in whole platelets (P1), larger 
platelets (P2), and smaller platelets (P3) 
were measured. There are preferential 
and higher expressions of P-selectin 
and activated αIIbβ3 (PAC-1 binding) in 
P2 platelets compared to those in P1 
and P3. B, Distribution of platelets to 
the large and small platelet populations. 
In the same experiments as panel A, 
the number of platelets in P1-P3 are 
calculated as a percentage of events from 
the flow cytometry data. All the data were 
determined twice by flow cytometer, 
and their mean values were plotted with 
standard deviation
60 000
40 000
20 000
6000
4000
2000
0
5000
80 000
0
0.050.00 0.10
0.00 0.05 0.10 0.15 0.20 0.25 0.00
100
80
60
40
20
0
120
140
160
180
200
P1
P3
P2
P1
P3
P2
P1
P3
P2
P1
P3
P2
0.05 0.10 0.15 0.20 0.25
0.050.00 0.10
Thr (u/mL) Thr (u/mL)
Thr (u/mL)
Thr (u/mL)
Thr (u/mL)
0
10 000
204-11Fab CD62P
P2/P1 ratio
Pac 1
204Fab
CD62P
Pac 1
Pe
rc
e
n
t o
f t
ot
al
 e
ve
n
ts
P2
/P
1 
%
M
FI
M
FI
M
FI
0.050.00 0.10 0.15 0.20 0.25
(A)
(B)
292  |     MOROI et al.
isolated and analyzed by western blotting. Western blotting with anti-
GPIb (Figure 5A-C) detected low-molecular-weight GPIb (glycocalicin) in 
the platelet supernatant; its amount increased after platelet activation by 
any agonist. The pellet-fraction lane contained one-third the amount of 
loaded protein compared to the supernatant lane, so most of the GPIb 
is still in the platelets. However, the supernatant of resting or activated 
platelets contained similar amounts of faint bands of GPVI, with the same 
mobility as native GPVI and no degraded (shed) GPVI.16
3.5 | Internalization of GPIb and GPVI in 
activated platelets
Platelets, prelabeled with Alexa Fluor-488–conjugated antibodies 
against GPIb or GPVI, were activated by Cvx or thrombin, fixed, and 
immobilized on poly-l-Lys-coated dishes. The immobilized platelets 
were stained with Alexa Fluor-647–conjugated anti-αIIbβ3 anti-
body to clearly visualize the cell membrane. Cvx-activated platelets 
F I G U R E  5   Immunoblotting analyses to determine if glycoprotein (GP) Ib and GPVI shedding occurs. Washed platelets were activated 
under the same conditions as used for the receptor expression analysis by flow cytometry and separated into the supernatant and pellet 
(platelets) fractions by centrifugation. Pellets are dissolved by SDS/urea so that they were the same volume as the supernatant samples 
and analyzed by immunoblotting. A, The immunoblotting of platelet pellets and (B) shows the results from the supernatants. Lane 1 (resting 
platelets), Lane 2 (crosslinked collagen-related peptide [CRP-XL]–activated platelets), Lane 3 (convulxin [Cvx]-activated platelets), Lane 4 
(thrombin-activated platelets) P ( control platelets). C, The results from quantitation of these bands. Two SDS/immunoblotting analysis 
were done for the experiment and the graph indicates the means of band densities with standard deviation. *P ≤ .05, **P ≤ .005. These data 
indicate the shedding of GPIb from the activated platelets, but GPVI is not shed
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stained for GPVI show strong granule-like fluorescence inside the 
platelets, while thrombin-activated or resting platelets show only 
diffuse staining over the whole cell (Figure 6A). Cvx- and thrombin-
activated platelets stained for GPIb show similar strong staining in-
side the cells, and resting platelets show diffuse staining over the 
whole cell (Figure 6B). These results show that GPVI is internalized 
in Cvx-activated platelets and GPIb is internalized in Cvx- and throm-
bin-activated platelets.
GPVI internalization was confirmed by treating thrombin- or 
Cvx-activated 1G5-SS-biotin-Alexa Fluor 647–streptavidin labeled 
platelets with the membrane-impermeable reducing agent TCEP 
(Figure 7). The MFI values of these platelets changed after TCEP 
treatment from 693.5 to 357.7 (resting platelets), 999.4 to 1042.4 
(Cvx-activated platelets) and 671.1 to 448.2 (thrombin-activated 
platelets). Figure 7 shows that TCEP removes most of the fluores-
cence in the resting or thrombin-treated platelets, indicating no in-
ternalization (ie, fluorescence confined to the platelet surface), but 
the fluorescence of the Cvx-treated platelets remains intact, con-
firming internalization.
3.6 | Exposure of intracellular receptors on 
platelet spreading
Our flow cytometry data suggest that additional receptors are newly 
exposed on the platelet surface after platelet activation. Preexisting 
surface receptors were differentiated from newly exposed ones 
by allowing platelets labeled with Alexa Fluor-488–conjugated re-
ceptor-specific antibody to adhere and spread on immobilized col-
lagen or fibrinogen and then post-staining with the same antibody 
conjugated with Alexa Fluor-647. For GPVI dimers, platelets were 
prestained with Alexa Fluor-488 204-11 Fab and post-stained with 
AlexaFluor-647-1G5, since 204-11 does not react with fixed plate-
lets. Anti–GPVI dimer prelabeled platelets spread well on immobi-
lized fibrinogen; prelabeled GPVI is localized on the cell body, but 
post-stained GPVI appears in the membrane, at the edges of the 
lamellipodia, of spread cells (Figure 8A). The GPIb-prestained cells 
are less spread but show differential staining similar to GPVI.
Platelets adhered to collagen (Figure 8B) have GPVI clusters 
along the collagen fibers, as previously reported,15 with prestained 
F I G U R E  6   Analyses of internalization. 
Platelets are prelabeled with Alexa 
Fluor-488–conjugated 204-11 Fab 
(anti–GPVI dimer; A) or Alexa Fluor-488–
conjugated anti-GPIb (clone 486805; 
B) and then activated with convulxin 
(Cvx) or thrombin. Platelets were fixed 
with formaldehyde/glutaraldehyde 
solution as described in the text and 
internalization of labeled antibody/
antigen complex (green) was analyzed by 
confocal microscopy after staining with 
Alexa Fluor-647–conjugated anti-integrin 
αIIbβ3 (red) to allow clear visualization of 
the platelet plasma membrane. The data 
show that GPVI dimers of Cvx-activated 
platelets and GPIb of Cvx- and thrombin-
activated platelets are internalized. The 
images are typical of the results from four 
experiments; in each experiment, 5-8 
fields of the sample were imaged for each 
condition
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and post-stained GPVI colocalized. This suggests that both preex-
isting and newly exposed GPVI moved to collagen’s platelet-bind-
ing sites. Prestained GPIb is concentrated on the cell body, whereas 
post-stained GPIb is diffuse and mostly localized to the lamellipodia 
of the spread platelet; this is different from the platelets adhered 
to fibrinogen, as collagen strongly activated the platelets. However, 
prestained and post-stained αIIbβ3 are mainly colocalized, but 
strong prestaining is observed in the cell body. These results show 
that when platelets spread and a receptor does not interact with 
substrate, preexisting surface receptors reside at the cell body, while 
newly exposed receptors present at the edges of the lamellipodia in 
the spread platelet. If receptors react with substrate, preexisting and 
newly exposed receptors move to the binding site. Such conditions 
are typically present for GPVI on platelets adhering on fibrinogen 
and collagen.
4  | DISCUSSION
This study demonstrates that platelet activation changes the levels 
of major glycoprotein receptors, either decreasing or increasing their 
surface expressions depending on both the receptor and the ago-
nist. PRP, washed platelets, and fixed platelets (Figures 2 and 3A) all 
showed increased expression of surface αIIbβ2 upon activation by 
CRP-XL, Cvx, or thrombin, but surface GPIb is decreased. Total and 
dimeric GPVI expressions markedly decreased after Cvx-induced 
activation, but the other agonists induced similar or increased 
expression. 1G5 can activate platelets, so total GPVI expression in 
CRP-XL- or thrombin-induced determined with this antibody did 
not differ from the resting level. These results suggest that platelet 
activation increases surface expression of some receptors, like the 
integrins, but decreases expressions of GPIb and GPVI through other 
mechanisms.
GPIb and GPVI are susceptible to cleavage by metalloprotein-
ases ADAM17 and ADAM10, respectively, after platelet activation, 
so their soluble forms, glycocalicin and 55-KD GPVI, respectively, 
may be released into the medium.16,17 Under the conditions of our 
flow cytometry assays, GPIb, as glycocalicin, was detectable in the 
supernatant, although most of it remained on the platelets (Figure 5), 
but almost no soluble GPVI was in the supernatant. No exogenous 
Ca2+ was added to our flow cytometry samples, so shedding of ei-
ther glycoprotein should be minimized in our assay condition. Cvx-
activated platelets have strong patch-like staining inside the cell, 
consistent with internalization of prestained GPVI (Figure 6). This 
was confirmed by our results showing that only the fluorescence of 
Cvx-stimulated 1G5-SS-biotin-streptavidin prelabeled platelets was 
resistant to cleavage by TCEP, whereas that of thrombin-activated 
or resting platelets was not (Figure 7). Cvx- or thrombin-activated 
GPIb-prestained platelets showed similar internal fluorescent aggre-
gates. Such GPIb internalization was previously observed,18‒21 but 
this is the first report of Cvx-specific GPVI internalization. Platelets 
produce microparticles containing plasma membrane after activa-
tion,22 which could reduce the receptor level in the remaining plasma 
membrane, but expressions of other receptors increased under the 
F I G U R E  7   Analysis of glycoprotein (GP) VI internalization using TCEP (tris[2-carboxyethyl]phosphine). Platelets were prelabeled with 
1G5-SS-biotin and Alexa Fluor-647–streptavidin and activated with convulxin (Cvx; 1 µg/mL) or thrombin (0.2 unit/mL). The platelets 
were reacted with 28 mmol/L TCEP in the presence of 5 mmol/L ethylenediaminetetraacetic acid for 10 min following with washing with 
citrate-buffered saline. The platelets were resuspended in modified HEPES (4-[2-hydroxyethyl]-1piperazineethanesulfonic acid)–Tyrode’s 
buffer, fixed with 1% paraformaldehyde, washed, plated on poly-Lys coated MatTek dishes, and analyzed with confocal microscopy. TCEP 
removes all the fluorescence in the resting or thrombin-treated platelets, indicating no internalization (ie, fluorescence confined to the 
platelet surface). However, the fluorescence of the Cvx-treated platelets remains intact, confirming internalization. The right-hand panel 
shows a schematic representation of how this experiment. This experiment was performed twice, with each giving similar results; in each 
experiment, 5-8 fields of the sample were imaged for each condition
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same conditions, so this would contribute little to decreases in GPIb 
and GPVI.
Increased receptor expression after activation could be explained 
by the merging of OCS and granule membranes with the surface mem-
brane, which translocate intracellular receptors to the platelet sur-
face.1‒4,18,19 Thus, we can reasonably hypothesize that GPIb and GPVI 
expressions would first increase upon platelet activation and then 
decrease due to internalization, shedding, or both. Thrombin-induced 
increase in surface GPVI and its Cvx-induced decrease occur on similar 
time scales (Figure 3B), so GPVI internalization by Cvx must be rapid 
if intracellular GPVI is first cell-surface–expressed and then internal-
ized. The observed differential expressions of surface GPVI induced by 
thrombin and Cvx raises several possibilities about the internalization 
process: GPVI expression may be increased by thrombin activation 
through a mechanism similar to that for the increase in αIIbβ3, while 
direct binding of Cvx to GPVI may induce GPVI internalization. Our 
results suggest that large-cluster formation may be required to induce 
strong internalization since CRP-XL produces little internalization. Cvx 
is a tetramer of heterodimers,23 and while CRP-XL is a crosslinked 
molecule, it is composed of single triple-helical peptides, which do not 
bind to GPVI.10 Thus, only Cvx would form dense GPVI clusters large 
enough to induce internalization.
In contrast to GPVI, many agonists have been reported to de-
crease GPIb expression,21,24 suggesting platelet activation in general 
would cause GPIb internalization. Electron micrographs suggested 
cytoskeletal involvement in GPIb internalization.19‒21 However, 
αIIbβ3 binds to the cytoskeleton as well and is clustered after activa-
tion but does not internalize, so the precise mechanism of internal-
ization remains inconclusive.
Using prestaining and post-staining with receptor-specific anti-
bodies labeled with fluorophores that emit fluorescence of differ-
ent wavelengths, we differentiated preexisting surface receptors 
in resting platelets from intracellular receptors newly exposed 
upon platelet activation. Prestained GPVI on fibrinogen-adhered 
platelets localizes to the cell body in the center of the spread cell, 
while post-stained GPVI localizes at the edges of the spread cell 
(Figure 8A). However, platelets adhered on collagen show colocal-
ization of prestained and post-stained GPVI clustered along the 
collagen fibers, as previously reported.15 These results indicate 
that the flat, spread membrane of fibrinogen-adhered platelets 
would come from an intracellular resource, with newly exposed 
GPVI dispersed freely over the lamellipodia, but originally exist-
ing surface GPVI would remain at the same place. However, be-
cause of GPVI’s high affinity for collagen, prestained (green) and 
F I G U R E  8   Colocalization analysis of 
prelabeled and postlabeled receptors 
on adhered platelets. Platelets were 
prelabeled with Alexa Fluor-488–
conjugated antibodies and were allowed 
to adhere on fibrinogen- or collagen-
coated surfaces. The adhered platelets 
were fixed and stained with Alexa 
Fluor-647conjugates of the corresponding 
antibodies. For platelets adhered to 
immobilized fibrinogen, post-staining 
shows the new expression of GPVI and 
GPIb, derived from intracellular GPVI and 
GPIb, on the surface membrane of spread 
cells, while the prestained receptors 
localized to the cell body. On the other 
hand, both pre- and post-stained GPVI is 
essentially all confined to the clusters of 
GPVI adhered to the collagen fibers. This 
figure gives representative results from 1 
of 3 experiments, all giving similar results; 
in each experiment, 5-8 fields of the 
sample were imaged for each condition
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post-stained GPVI (red) would move to the region of the mem-
brane in contact with collagen fibers and become colocalized as 
membrane clusters on the fibers (yellow; Figure 8B). Distribution 
of prestained and post-stained GPIb on platelets adhered to immo-
bilized fibrinogen and collagen are essentially like that of GPVI on 
platelets adhered on fibrinogen, but since these platelets are not 
fully spread like the GPVI-stained platelets, many of the spread 
cells show only a small separation of post- and prestaining. These 
results suggest that intracellular receptors become exposed in the 
spread membrane (lamellipodia) of adhered platelets and localize 
separately from the originally expressed surface receptors when 
they do not interact with substrate.
The P2/P1 ratio is increased upon activation, consistent with 
the larger platelets expressing more receptors on their surface 
compared to the smaller platelets. These results suggest that larger 
platelets are more activated than smaller platelets, as reported be-
fore.25‒28 Upon thrombin activation, P-selectin and PAC-1 expres-
sions in the larger platelets are increased much more than in the total 
and smaller platelets (Figure 4A). At higher thrombin concentrations, 
P-selectin and PAC-1 expressions in P2 became about 2-fold and 
3-fold higher than that of P1 and P3, respectively. Since gating by 
flow cytometry cannot totally separate the larger platelets from 
the smaller platelets, these results suggest that activation involving 
integrin activation and secretion would mainly occur in the larger 
platelet population.
The large-platelet fraction isolated by differential centrifuga-
tion or flow cytometry was reported to be more active,25‒27 and 
a relationship between activity and platelet size was reported.28 
Although young platelets were thought to be large and more ac-
tive, platelet size and age were indicated to independently affect 
platelet function.29,30 Heterogeneity of platelet size was suggested 
to come from the heterogeneity of megakaryocytes31 and activa-
tion of the mechanistic target of rapamycin complex1 in megakary-
ocytes may contribute to elevated platelet volume,9 suggesting 
that megakaryocytes would produce different sizes of platelets 
and that the larger platelet subpopulation would have higher ac-
tivities. Our data indicate that the larger subpopulation of acti-
vated platelets showed a higher level of agonist-induced receptor 
expression compared to the total platelet population, supporting 
the previous reports describing that larger platelets have higher 
activities. In this context, it is very interesting that a larger MPV 
has been indicated to be a risk factor for cardiovascular disease in 
both men and women7,8,32 or just in men.33 Our results importantly 
suggest that the large-platelet subpopulation would be the main 
contributor to higher platelet activity and our method, analyzing 
the receptor expression of resting and activated platelets by flow 
cytometry, would be a good method to analyze the risk factor of 
having larger platelets.
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